We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Design Therapeutics
DSGN
$765M
| $14.1K | ﹤0.01% |
4,200
-6,118
| -59% | -$23.8K |
|
1752
ALX Oncology
ALXO
$261M
| $14K | ﹤0.01% |
2,329
-199,033
| -99% | -$2.45M |
|
1753
Rimini Street
RMNI
$427M
| $13.9K | ﹤0.01% |
4,540
-32,066
| -88% | -$88.1K |
|
1754
Federal Realty Investment Trust
FRT
$9.9B
| $13.9K | ﹤0.01% |
138
-8
| -5% | -$807 |
|
1755
Healthcare Services Group
HCSG
$1.5B
| $13.9K | ﹤0.01% |
1,311
+318
| +32% | +$3.53K |
|
1756
Rush Enterprises Class B
RUSHB
$6.28B
| $13.7K | ﹤0.01% |
522
+33
| +7% | +$951 |
|
1757
Entrada Therapeutics
TRDA
$268M
| $13.5K | ﹤0.01% |
950
+62
| +7% | +$881 |
|
|
MITT
1758
TPG Mortgage Investment Trust
MITT
$204M
| $13.4K | ﹤0.01% |
2,022
+1,092
| +117% | +$6.97K |
|
1759
Toyota
TM
$231B
| $13.3K | ﹤0.01% |
65
+13
| +25% | +$2.88K |
|
1760
Solventum
SOLV
$15.3B
| $13.3K | ﹤0.01% |
+251
| New | +$15.2K |
|
1761
Vita Coco
COCO
$3.23B
| $13K | ﹤0.01% |
466
+298
| +177% | +$7.9K |
|
1762
Intrepid Potash
IPI
$520M
| $12.9K | ﹤0.01% |
551
-81,107
| -99% | -$1.87M |
|
1763
Veracyte
VCYT
$3.23B
| $12.4K | ﹤0.01% |
574
-51
| -8% | -$1.07K |
|
1764
ABM Industries
ABM
$2.93B
| $12.2K | ﹤0.01% |
241
-20
| -8% | -$933 |
|
1765
Diamondrock Hospitality Co
DRH
$2.54B
| $12.1K | ﹤0.01% |
1,433
-13,999
| -91% | -$122K |
|
|
THRD
1766
DELISTED
Third Harmonic Bio
THRD
| $11.5K | ﹤0.01% |
888
+49
| +6% | +$606 |
|
1767
Heritage Insurance Holdings
HRTG
$1.03B
| $11.5K | ﹤0.01% |
1,629
-247
| -13% | -$2.18K |
|
|
KLRS
1768
Kalaris Therapeutics
KLRS
$76.2M
| $11K | ﹤0.01% |
662
+1
| +0.2% | +$18 |
|
1769
Marathon Digital Holdings
MARA
$4.34B
| $10.8K | ﹤0.01% |
543
-14,592
| -96% | -$277K |
|
1770
HSBC
HSBC
$350B
| $10.7K | ﹤0.01% |
246
+14
| +6% | +$602 |
|
1771
Aclaris Therapeutics
ACRS
$813M
| $10.5K | ﹤0.01% |
9,539
+1,280
| +15% | +$1.5K |
|
|
GTHX
1772
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $10.3K | ﹤0.01% |
4,522
+2,490
| +123% | +$9.51K |
|
|
TEAD
1773
Teads Holding Co
TEAD
$44.8M
| $10.2K | ﹤0.01% |
2,047
+1,426
| +230% | +$6.33K |
|
1774
Franklin Templeton
BEN
$16.9B
| $10.2K | ﹤0.01% |
456
-227
| -33% | -$5.47K |
|
1775
Invesco
IVZ
$13.6B
| $10.1K | ﹤0.01% |
673
-148
| -18% | -$2.28K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.